Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis

Etrolizumab is an IgG1‐humanized monoclonal antibody that specifically targets the β7 subunit of α4β7 and α4Eβ7 integrins, and it has been evaluated for the treatment of moderately‐to‐severely active ulcerative colitis (UC). Population pharmacokinetic (PK) analysis was performed to characterize etro...

Descripción completa

Detalles Bibliográficos
Autores principales: Moein, Anita, Lu, Tong, Jönsson, Siv, Ribbing, Jakob, Kassir, Nastya, Zhang, Wenhui, Sperinde, Gizette, Zhang, Rong, Tang, Meina, Oh, Young S., Bruno, Rene, Zhu, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469700/
https://www.ncbi.nlm.nih.gov/pubmed/35851998
http://dx.doi.org/10.1002/psp4.12846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469700/
https://www.ncbi.nlm.nih.gov/pubmed/35851998
http://dx.doi.org/10.1002/psp4.12846

Ejemplares similares